Erratum: Genetic defects in the human glycome (Nature Reviews Genetics (2006) 7 (537-551) DOI: 10.1038/nrg1894);Genetic defects in the human glycome

Nature Reviews Genetics

Volumn 7, Issue 7, 2006, Pages 537-551

  Freeze, Hudson H ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; GLYCAN DERIVATIVE;

AMISH INFANTILE EPILEPSY; CHONDRODYSPLASIA; CLINICAL FEATURE; CONGENITAL DISORDER OF GLYCOSYLATION; CONGENITAL DISORDER OF GLYCOSYLATION IA; CONGENITAL DISORDER OF GLYCOSYLATION IB; CONGENITAL DISORDER OF GLYCOSYLATION IC; CONGENITAL DISORDER OF GLYCOSYLATION ID; CONGENITAL DISORDER OF GLYCOSYLATION IE; CONGENITAL DISORDER OF GLYCOSYLATION IF; CONGENITAL DISORDER OF GLYCOSYLATION IG; CONGENITAL DISORDER OF GLYCOSYLATION IH; CONGENITAL DISORDER OF GLYCOSYLATION II; CONGENITAL DISORDER OF GLYCOSYLATION IIA; CONGENITAL DISORDER OF GLYCOSYLATION IIB; CONGENITAL DISORDER OF GLYCOSYLATION IIC; CONGENITAL DISORDER OF GLYCOSYLATION IID; CONGENITAL DISORDER OF GLYCOSYLATION IIE; CONGENITAL DISORDER OF GLYCOSYLATION IIF; CONGENITAL DISORDER OF GLYCOSYLATION IJ; CONGENITAL DISORDER OF GLYCOSYLATION IK; CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE 2; CONGENITAL MUSCULAR DYSTROPHY 1C; CONGENITAL MUSCULAR DYSTROPHY 1D; EHLERS DANLOS SYNDROME; FAMILIAL TUMORAL CALCINOSIS; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; GENE MUTATION; GENETIC COMPLEMENTATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; GENOME SIZE; GLYCOSYLATION; GOLGI COMPLEX; HEREDITARY INCLUSION BODY MYOPATHY II; HEREDITARY MULTIPLE EXOSTOSIS; HUMAN; HUMAN GENOME; MACULAR CORNEAL DYSTROPHY I; MACULAR CORNEAL DYSTROPHY II; MUCOLIPIDOSIS TYPE 2; MUCOLIPIDOSIS TYPE 3; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SPONDYLOEPIPHYSEAL DYSPLASIA; TN SYNDROME; WALKER WARBURG SYNDROME;

EID: 33745381312     PISSN: 14710056     EISSN: 14710064     Source Type: Journal    
DOI: 10.1038/nrg1937     Document Type: Erratum

References (122)

1. Raman, R., Raguram, S., Venkataraman, G., Paulson, J. C. & Sasisekharan, R. Glycomics: an integrated systems approach to structure-function relationships of glycans. Nature Methods 2, 817-824 (2005). A 'one-stop shopping' guide that explains how to connect structure-function relationships in glycobiology.
2. Wopereis, S., Lefeber, D. J., Morava, E. & Wevers, R. A. Mechanisms in protein O-glycan biosynthesis and clinical and molecular aspects of protein O-glycan biosynthesis defects: a review. Clin. Chem. 52, 574-600 (2006).
3. Jaeken, J. Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it! J. Inherit. Metab. Dis. 26, 99-118 (2003).
4. Muntoni, F. Journey into muscular dystrophies caused by abnormal glycosylation. Acta Myol. 23, 79-84 (2004).
5. Spiro, R. G. Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12, 43R-56R (2002).
6. Kornfeld, R. & Kornfeld, S. Assembly of asparagine-linked oligosaccharides. Annu. Rev. Biochem. 54, 631-664 (1985). A classic description of N-glycan biosynthesis; this review is clear and detailed.
7. Chavan, M. & Lennarz, W. The molecular basis of coupling of translocation and N-glycosylation. Trends Biochem. Sci. 31, 17-20 (2006).
8. Kelleher, D. J. & Gilmore, R. An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology 16, 47R-62R (2006).
9. Schachter, H., Vajsar, J. & Zhang, W. The role of defective glycosylation in congenital muscular dystrophy. Glycoconj. J. 20, 291-300 (2004).
10. Chai, W. et al. High prevalence of 2-mono- and 2,6-di-substituted manol-terminating sequences among O-glycans released from brain glycopeptides by reductive alkaline hydrolysis. Eur. J. Biochem. 263, 879-888 (1999).
11. Marth, J. D. in Essentials of Glycobiology (eds Varki, A. et al.) 101-113 (Cold Spring Harbor Laboratory Press, New York, 1999).
12. Esko, J. in Essentials of Glycobiology (eds Varki, A. et al.) 145-160 (Cold Spring Harbor Laboratory Press, New York, 1999).
13. Esko, J. D. & Selleck, S. B. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu. Rev. Biochem. 71, 435-471 (2002).
14. Varki, A. in Essentials of Glycobiology (eds Varki, A. et al.) 115-129 (Cold Spring Harbor Laboratory Press, New York, 1999).
15. Hakomori, S. Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization. Glycoconj. J. 21, 125-137 (2004).
16. Hwa, K. Y. Glycosyl phosphatidylinositol-linked glycoconjugates: structure, biosynthesis and function. Adv. Exp. Med. Biol. 491, 207-214 (2001).
17. Hancock, J. F. GPI-anchor synthesis: Ras takes charge. Dev. Cell 6, 743-745 (2004).
18. Jaeken, J. & Matthijs, G. Congenital disorders of glycosylation. Annu. Rev. Genomics Hum. Genet. 2, 129-151 (2001).
19. Aebi, M. et al. Carbohydrate-deficient glycoprotein syndromes become congenital disorders of glycosylation: an updated nomenclature for CDG. First International Workshop on CDGS. Glycoconj. J. 16, 669-671 (1999).
20. Hagberg, B. A., Blennow, G., Kristiansson, B. & Stibler, H. Carbohydrate-deficient glycoprotein syndromes: peculiar group of new disorders. Pediatr. Neurol. 9, 255-262 (1993).
21. Freeze, H. H. Update and perspectives on congenital disorders of glycosylation. Glycobiology 11, 129R-143R (2001).
22. Jaeken, J., Matthijs, G., Carchon, H. & Schaftingen, E. V. in The Metabolic & Molecular Bases of Inherited Diseases (eds Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, D.) 1601-1622 (McGraw-Hill Medical Publishing Division, New York, 2001).
23. Marquardt, T. & Denecke, J. Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur. J. Pediatr. 162, 359-379 (2003).
24. Grünewald, S., Schollen, F., Van Schaftingen, F., Jaeken, J. & Matthijs, G. High residual activity of PMM2 in patients' fibroblasts: possible pitfall in the diagnosis of CDG-Ia (phosphomannomutase deficiency). Am. J. Hum. Genet. 68, 347-354. (2001).
25. van Ommen, C. H. et al. Carbohydrate-deficient glycoprotein syndrome type 1a: a variant phenotype with borderline cognitive dysfunction, cerebellar hypoplasia, and coagulation disturbances. J. Pediatr. 136, 400-403 (2000).
26. Briones, P. et al. Biochemical and molecular studies in 26 Spanish patients with congenital disorder of glycosylation type Ia. J. Inherit. Metab. Dis. 25, 635-646 (2002).
27. Coman, D., Klingberg, S., Morris, D., McGill, J. & Mercer, H. Congenital disorder of glycosylation type Ia in a 6-year-old girl with a mild intellectual phenotype: two novel PMM2 mutations. J. Inherit. Metab. Dis. 28, 1189-1190 (2005).
28. Matthijs, G., Schollen, E., Heykants, L. & Grünewald, S. Phosphomannomutase deficiency: the molecular basis of the classical Jaeken syndrome (CDGS type Ia). Mol. Genet. Metab. 68, 220-226 (1999).
29. Pirard, M. et al. Effect of mutations found in carbohydrate-deficient glycoprotein syndrome type IA on the activity of phosphomannomutase 2. FEBS Lett. 452, 319-322 (1999).
30. Kjaergaard, S., Skovby, F. & Schwartz, M. Carbohydrate-deficient glycoprotein syndrome type 1A: expression and characterisation of wild type and mutant PMM2 in E. coli. Eur. J. Hum. Genet. 7, 884-888 (1999).
31. Westphal, V. et al. Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia. Genet. Med. 3, 393-398 (2001).
32. Schollen, E., Kjaergaard, S., Legius, E., Schwartz, M. & Matthijs, G. Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia). Eur. J. Hum. Genet. 8, 367-371 (2000).
33. Westphal, V., Xiao, M., Kwok, P. Y. & Freeze, H. H. Identification of a frequent variant in ALG6, the cause of congenital disorder of glycosylation-Ic. Hum. Mutat. 22, 420-421 (2003).
34. Niehues, R. et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J. Clin. Invest. 101, 1414-1420 (1998). First description of a novel glycosylation disease, its genetic basis, and a successful 'low-tech' treatment.
35. Denecke, J. et al. Congenital disorder of glycosylation type Id: clinical phenotype, molecular analysis, prenatal diagnosis, and glycosylation of fetal proteins. Pediatr. Res. 58, 248-253 (2005).
36. Tan, J., Dunn, J., Jaeken, J. & Schachter, H. Mutations in the MGAT2 gene controlling complex N-glycan synthesis cause carbohydrate-deficient glycoprotein syndrome type II, an autosomal recessive disease with defective brain development. Am. J. Hum. Genet. 59, 810-817 (1996).
37. Jaeken, J. et al. Carbohydrate deficient glycoprotein syndrome type II: a deficiency in Golgi localised N-acetyl-glucosaminyltransferase II. Arch. Dis. Child. 71, 123-127 (1994).
38. Hansske, B. et al. Deficiency of UDP-galactose:N-acetylglucosamine β-1,4-galactosyltransferase I causes the congenital disorder of glycosylation type IId. J. Clin. Invest. 109, 725-733 (2002).
39. Lübke, T. et al. Complementation cloning identifies CDG-IIc, a new type of congenital disorders of glycosylation, as a GDP-fucose transporter deficiency. Nature Genet. 28, 73-76 (2001).
40. Martinez-Duncker, I. et al. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. Blood 105, 2671-2676 (2005).
41. Marquardt, T. et al. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood 94, 3976-3985 (1999).
42. Marquardt, T. et al. Leukocyte adhesion deficiency II syndrome, a generalized defect in fucose metabolism. J. Pediatr. 134, 681-688 (1999).
43. Etzioni, A. et al. Brief report: recurrent severe infections caused by a novel leukocyte adhesion deficiency. N. Engl. J. Med. 327, 1789-1792 (1992).
44. Willig, T. B. et al. Macrothrombocytopenia with abnormal demarcation membranes in megakaryocytes and neutropenia with a complete lack of sialyl-Lewis-X antigen in leukocytes - a new syndrome? Blood 97, 826-828 (2001).
45. Spaapen, L. J. et al. Clinical and biochemical presentation of siblings with COG-7 deficiency, a lethal multiple O- and N-glycosylation disorder. J. Inherit. Metab. Dis. 28, 707-714 (2005).
46. Wu, X. et al. Mutation of the COG complex subunit gene COG7 causes a lethal congenital disorder. Nature Med. 10, 518-523 (2004). First description of a patient with a defect in trafficking of glycosyltransferases and nucleotide sugar transporters.
47. Steet, R. & Kornfeld, S. COG-7-deficient human fibroblasts exhibit altered recycling of Golgi proteins. Mol. Biol. Cell 17, 2312-2321 (2006).
48. Ungar, D., Oka, T., Krieger, M. & Hughson, F. M. Retrograde transport on the COG railway. Trends Cell Biol. 16, 113-120 (2006).
49. Oka, T. et al. Genetic analysis of the subunit organization and function of the conserved oligomeric golgi (COG) complex: studies of COG5- and COG7-deficient mammalian cells. J. Biol. Chem. 280, 32736-32745 (2005).
50. Shestakova, A., Zolov, S. & Lupashin, V. COG complex-mediated recycling of Golgi glycosyltransferases is essential for normal protein glycosylation. Traffic 7, 191-204 (2006).
51. Kubota, Y., Sano, M., Coda, S., Suzuki, N. & Nishiwaki, K. The conserved oligomeric Golgi complex acts in organ morphogenesis via glycosylation of an ADAM protease in C. elegans. Development 133, 263-273 (2006).
52. Wopereis, S. et al. Apolipoprotein C-III isofocusing in the diagnosis of genetic defects in O-glycan biosynthesis. Clin. Chem. 49, 1839-1845 (2003).
53. Morava, E. et al. Defective protein glycosylation in patients with cutis laxa syndrome. Eur. J. Hum. Genet. 13, 414-421 (2005).
54. Wopereis, S. et al. Patients with unsolved congenital disorders of glycosylation type II can be subdivided in six distinct biochemical groups. Glycobiology 15, 1312-1319 (2005).
55. Matthijs, G. et al. Deficiencies in different subunits of the Conserved Oligomeric Golgi (COG) complex define a novel group of Congenital Disorder of Glycosylation. Am. Soc. Genet. Annu. Meeting 27 October 2005; available from the ASGH Abstract Search and Personal Itinerary Planner web page, 〈http://www.ashg.org/genetics/ashg05s〉.
56. Foulquier, F. et al. Conserved oligomeric Golgi complex subunit 1 deficiency reveals a previously uncharacterized congenital disorder of glycosylation type II. Proc. Natl Acad. Sci. USA 103, 3764-3769 (2006).
57. Sacher, M. Membrane traffic fuses with cartilage development. FEBS Lett. 550, 1-4 (2003).
58. Mandato, C. et al. Cryptogenic liver disease in four children: a novel congenital disorder of glycosylation. Pediatr. Res. 59, 293-298 (2006).
59. Wang, Y. et al. Modeling human congenital disorder of glycosylation type IIa in the mouse: conservation of asparagine-linked glycan-dependent functions in mammalian physiology and insights into disease pathogenesis. Glycobiology 11, 1051-1070 (2001).
60. Becker, D. J. & Lowe, J. B. Fucose: biosynthesis and biological function in mammals. Glycobiology 13, 41R-53R (2003).
61. Lühn, K., Wild, M. K., Eckhardt, M., Gerardy-Schahn, R. & Vestweber, D. The gene defective in leukocyte adhesion deficiency II encodes a putative GDP-fucose transporter. Nature Genet. 28, 69-72. (2001).
62. Freeze, H. H. & Aebi, M. Altered glycan structures: the molecular basis of congenital disorders of glycosylation. Curr. Opin. Struct. Biol. 15, 490-498 (2005).
63. Ghosh, P., Dahms, N. M. & Kornfeld, S. Mannose 6-phosphate receptors: new twists in the tale. Nature Rev. Mol. Cell Biol. 4, 202-212 (2003).
64. Kudo, M., Brem, M. S. & Canfield, W M. Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-Hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase α/β-subunits precursor gene. Am. J. Hum. Genet. 78, 451-463 (2006).
65. Tiede, S. et al. Mucolipidosis II is caused by mutations in GNPTA encoding the α/β GlcNAc-1-phosphotransferase. Nature Med. 11, 1109-1112 (2005).
66. Fukuda, M. N. HEMPAS. Hereditary erythroblastic multinuclearity with positive acidified serum lysis test. Biochim. Biophys. Acta 1455, 231-239 (1999).
67. Chui, D. et al. α-Mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis. Cell 90, 157-167 (1997).
68. Leslie, N. D. Insights into the pathogenesis of galactosemia. Annu. Rev. Nutr. 23, 59-80 (2003).
69. Lai, K., Langley, S. D., Khwaja, F. W., Schmitt, E. W. & Elsas, L. J. GALT deficiency causes UDP-hexose deficit in human galactosemic cells. Glycobiology 13, 285-294 (2003).
70. Sturiale, L. et al. Hypoglycosylation with increased fucosylation and branching of serum transferrin N-glycans in untreated galactosemia. Glycobiology 15, 1268-1276 (2005). Patients with uncontrolled galactosaemia show severe underglycosylation of serum proteins, which provides insights into the potential cause of pathogenesis in this disorder.
71. Prestoz, L. L., Couto, A. S., Shin, Y. S. & Petry, K. G. Altered follicle stimulating hormone isoforms in female galactosaemia patients. Eur. J. Pediatr. 156, 116-120 (1997).
72. Ridel, K. R., Leslie, N. D. & Gilbert, D. L. An updated review of the long-term neurological effects of galactosemia. Pediatr. Neurol. 33, 153-161 (2005).
73. Senger, R. S. & Karim, M. N. Variable site-occupancy classification of N-linked glycosylation using artificial neural networks. Biotechnol. Prog. 21, 1653-1662 (2005).
74. Jones, J., Krag, S. S. & Betenbaugh, M. J. Controlling N-linked glycan site occupancy. Biochim. Biophys. Acta 1726, 121-137 (2005).
75. Nishikawa, A. & Mizuno, S. The efficiency of N-linked glycosylation of bovine DNase I depends on the Asn-Xaa-Ser/Thr sequence and the tissue of origin. Biochem. J. 355, 245-248 (2001).
76. Welch, W. J. Role of quality control pathways in human diseases involving protein misfolding. Semin. Cell Dev. Biol. 15, 31-38 (2004).
77. Lonnqvist, L. et al. A point mutation creating an extra N-glycosylation site in fibrillin-1 results in neonatal Marfan syndrome. Genomics 36, 468-475 (1996).
78. Raghunath, M., Kielty, C. M. & Steinmann, B. Truncated profibrillin of a Marfan patient is of apparent similar size as fibrillin: intracellular retention leads to over-N-glycosylation. J. Mol. Biol. 248, 901-909 (1995).
79. Vogt, G. et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nature Genet. 37, 692-700 (2005). A surprising discovery: mutations that create occupied N-glycosylation sites are pathological. Random insertion of glycans might disrupt assembly of signalling complexes.
80. Morgan, R. et al. N-acetylglucosaminyltransferase V (Mgat5)-mediated N-glycosylation negatively regulates Th1 cytokine production by T cells. J. Immunol. 173, 7200-7208 (2004).
81. Martin, P. T. & Freeze, H. H. Glycobiology of neuromuscular disorders. Glycobiology 13, 67R-75R (2003).
82. Muntoni, F. & Voit, T. The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul. Disord. 14, 635-649 (2004).
83. van Reeuwijk, J., Brunner, H. G. & van Bokhoven, H. Glyc-O-genetics of Walker-Warburg syndrome. Clin. Genet. 67, 281-289 (2004).
84. Muntoni, F., Brockington, M., Torelli, S. & Brown, S. C. Defective glycosylation in congenital muscular dystrophies. Curr. Opin. Neurol. 17, 205-209 (2004).
85. Wilier, T. et al. Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc. Natl Acad. Sci. USA 101, 14126-14131 (2004).
86. Manya, H. et al. Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc. Natl Acad. Sci. USA 101, 500-505 (2004).
87. van Reeuwijk, J. et al. POMT2 mutations cause alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet. 42, 907-912 (2005).
88. Yoshida, A. et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1, 717-724 (2001).
89. Taniguchi, K. et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum. Mol. Genet. 12, 527-534 (2003).
90. Liu, J. et al. A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). Mech. Dev. 123, 228-240 (2006).
91. Mercuri, E. et al. Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch. Neurol. 63, 251-257 (2006).
92. Kanagawa, M. et al. Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell 117, 953-964 (2004).
93. Barresi, R. et al. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med. 10, 696-703 (2004). References 92 and 93 stress the importance of LARGE and provide insights into how it might function.
94. Nguyen, H. H., Jayasinha, V., Xia, B., Hoyte, K. & Martin, P. T. Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc. Natl Acad. Sci. USA 99, 5616-5621 (2002).
95. Rando, T. A. Artificial sweeteners - enhancing glycosylation to treat muscular dystrophies. N. Engl. J. Med. 351, 1254-1256 (2004).
96. Engvall, E. & Wewer, U. M. The new frontier in muscular dystrophy research: booster genes. FASEB J. 17, 1579-1584 (2003).
97. Gotte, M. & Kresse, H. Defective glycosaminoglycan substitution of decorin in a patient with progeroid syndrome is a direct consequence of two point mutations in the galactosyltransferase I (β4GalT-7) gene. Biochem. Genet. 43, 65-77 (2005).
98. Zak, B. M., Crawford, B. E. & Esko, J. D. Hereditary multiple exostoses and heparan sulfate polymerization. Biochim. Biophys. Acta 1573, 346-355 (2002).
99. Jaeken, J. & Carchon, H. Congenital disorders of glycosylation: a booming chapter of pediatrics. Curr. Opin. Pediatr. 16, 434-439 (2004).
100. Lin, X. et al. Disruption of gastrulation and heparan sulfate biosynthesis in EXT1-deficient mice. Dev. Biol. 224, 299-311 (2000).
101. Stickens, D., Zak, B. M., Rougier, N., Esko, J. D. & Werb, Z. Mice deficient in Ext2 lack heparan sulfate and develop exostoses. Development 132, 5055-5068 (2005).
102. Dawson, P. A. & Markovich, D. Pathogenetics of the human SLC26 transporters. Curr. Med. Chem. 12, 385-396 (2005).
103. Venkatachalam, K. V. Human 3′-phosphoadenosine 5′- phosphosulfate (PAPS) synthase: biochemistry, molecular biology and genetic deficiency. IUBMB Life 55, 1-11 (2003).
104. Ten Hagen, K. G., Fritz, T. A. & Tabak, L. A. All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosa minyltransferases. Glycobiology 13, 1R-16R (2003).
105. Fukumoto, S. Post-translational modification of Fibroblast Growth Factor 23. Ther. Apher. Dial. 9, 319-322 (2005).
106. Ju, T. & Cummings, R. D. Protein glycosylation: chaperone mutation in Tn syndrome. Nature 437, 1252 (2005). This paper indicates that somatic mutations that affect a glycosyltransferase-specific chaperone might be involved in autoimmune disease.
107. Simpson, M. A. et al. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nature Genet. 36, 1225-1229 (2004).
108. Yamashita, T. et al. Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl Acad. Sci. USA 102, 2725-2730 (2005).
109. Proia, R. L. Gangliosides help stabilize the brain. Nature Genet. 36, 1147-1148 (2004).
110. Smith, L. J. Paroxysmal nocturnal hemoglobinuria. Clin. Lab. Sci. 17, 172-177 (2004).
111. Hanaoka, N. et al. Immunoselection by natural killer cells of PICA mutant cells missing stress-inducible ULBP. Blood 107, 1184-1191 (2006).
112. Taniguchi, N., Nakamura, K., Narimatsu, H., von der Lieth, C. W. & Paulson, J. Human Disease Glycomics/Proteome Initiative workshop and the 4th HUPO annual congress. Proteomics 6, 12-13 (2006).
113. Sweet collaborations [Editorial]. Nature Methods 2, 799 (2005).
114. Young, W. W. Jr. Organization of Golgi glycosyltransferases in membranes: complexity via complexes. J. Membr. Biol. 198, 1-13 (2004).
115. Sprong, H. et al. Association of the Golgi UDP-galactose transporter with UDP-galactose:ceramide galactosyltransferase allows UDP-galactose import in the endoplasmic reticulum. Mol. Biol. Cell 14, 3482-3493 (2003).
116. Demetriou, M., Granovsky, M., Quaggin, S. & Dennis, J. W. Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409, 733-739. (2001). This paper reveals that modest changes in glycan structure can have dramatic, clinically important effects on signalling.
117. Ohtsubo, K. et al. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell 123, 1307-1321 (2005).
118. Reumers, J. et al. SNPeffect: a database mapping molecular phenotypic effects of human non-synonymous coding SNPs. Nucleic Acids Res. 33, D527-D532 (2005).
119. Westphal, V. et al. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. Am. J. Pathol. 157, 1917-1925 (2000).
120. Bode, L. & Freeze, H. H. Applied glycoproteomics - approaches to study genetic-environmental collisions causing protein-losing enteropathy. Biochim. Biophys. Acta 1760, 547-559 (2005).
121. Lenz, D. et al. Protein-losing enteropathy in patients with Fontan circulation: is it triggered by infection? Crit. Care 7, 185-190 (2003).
122. Eklund, E. A. & Freeze, H. H. The congenital disorders of glycosylation - a multifaceted group of syndromes. NeuroRx 3, 254-263 (2006).